Has Martin Matsumura, MD received payments from drug or device companies?

Yes. Drug and device makers reported $709 in general payments to Martin Matsumura, MD across 14 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Martin Matsumura, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Martin Matsumura, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Martin Matsumura, MD

Cardiovascular Disease · Wilkes Barre, PANPI 1821103946

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Edwards Lifesciences at 39.4% of the total. 2025 is the largest year on record at $282, 2.2 times the $126 reported in 2019. That places this record below the midpoint for cardiovascular disease clinicians in PA, where the typical reported total is $1,447.

$709in general payments, 2019–2025

Across 14 payments — averaging $50.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Edwards Lifesciences$279
Atricure, Inc.$150
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$95
Heartflow, Inc.$72
E.r. Squibb & Sons, L.L.C.$70
Medtronic$42

$1,133in research payments, 2019–2025

Across 4 payments — averaging $283.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

CSL Behring$1K
Amgen$5

What the payments were for

Food & beverage$709100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Edwards Lifesciences	2	$279
Atricure, Inc.	1	$150
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	4	$95
Heartflow, Inc.	3	$72
E.r. Squibb & Sons, L.L.C.	3	$70
Medtronic	1	$42

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$709 in reported general payments places this provider in the 35th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$105,978

Medicare patients

2,085

Services billed

3,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	286	$261,512
EntrestoSacubitril/Valsartan	59	$52,197
Repatha SureclickEvolocumab	54	$29,055
JardianceEmpagliflozin	39	$27,871
XareltoRivaroxaban	17	$13,499
BrilintaTicagrelor	16	$12,969
FarxigaDapagliflozin Propanediol	16	$11,177
Praluent PenAlirocumab	20	$9,454
Metoprolol Succinate	293	$5,434
Atorvastatin Calcium	151	$2,065
Amiodarone Hcl	40	$1,976
Eplerenone	22	$1,952
Rosuvastatin Calcium	110	$1,749
Carvedilol	181	$1,725
Torsemide	80	$1,483

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Wilkes Barre

Hemal GadaWormleysburg$1.8M
Benjamin KalsmithPgh$1.7M
Peter KoweyWynnewood$1.5M
Paul ForfiaPhiladelphia$1.2M
Quang BuiPhiladelphia$933K
Rhian DaviesYork$853K
Sarang MangalmurtiBryn Mawr$728K
Sabahat BokhariAllentown$578K
George GabrielPittsburgh$563K
Rajesh DaveCamp Hill$442K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →